Ascentage Pharma Group International (NASDAQ: AAPG) received investigational new drug clearance from the China Center for Drug Evaluation (CDE) for its next‑generation Bruton's tyrosine kinase (BTK) degrader, APG‑3288, on February 5 2026. The approval authorizes a multicenter, open‑label Phase I study in patients with relapsed or refractory B‑cell malignancies, including B‑cell lymphomas and chronic lymphocytic leukemia.
APG‑3288 is a PROTAC‑based degrader that targets BTK for proteasomal degradation, a mechanism designed to overcome resistance to existing BTK inhibitors. The drug follows a prior FDA approval in the United States, positioning Ascentage to pursue a simultaneous global development program and expand its portfolio of targeted protein‑degradation therapies.
The Phase I trial will enroll approximately 50–60 patients across multiple sites in China, with primary objectives of assessing safety, tolerability, pharmacokinetics, and preliminary efficacy. Secondary endpoints will include pharmacodynamic markers of BTK degradation and early signals of clinical activity. The study is expected to begin enrollment within weeks of the IND clearance and to generate data that will inform subsequent Phase II and registration plans.
This regulatory milestone is significant for Ascentage’s commercial strategy. China’s oncology market is projected to reach $70 billion by 2028, with hematologic malignancies accounting for a sizable share. APG‑3288 targets a patient population that often develops resistance to first‑generation BTK inhibitors, offering a potential competitive advantage over drugs such as ibrutinib and acalabrutinib. The approval also complements Ascentage’s existing China‑approved products—Olverembatinib and Lisaftoclax—which together generate a combined annual revenue of roughly $200 million. While the company continues to post operating losses, the IND clearance strengthens its pipeline and supports future revenue growth.
Dr. Yifan Zhai, Chief Medical Officer, emphasized that “receiving IND clearances from both the U.S. FDA and China’s CDE is a pivotal step in our global innovation strategy. APG‑3288 addresses an unmet clinical need in drug‑resistant hematologic malignancies, and we are committed to advancing the program expeditiously.”
Historically, Ascentage’s stock has reacted conservatively to positive news, with single‑day declines following regulatory approvals and clinical data releases. Analysts attribute this pattern to the early‑stage nature of the program and the company’s ongoing financial challenges, including negative cash flow and high leverage. Despite these headwinds, the China IND clearance is viewed as a forward‑looking development that could unlock substantial commercial upside if the drug demonstrates safety and efficacy in the planned trials.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.